Skip to content
Screener

Vertex Pharmaceuticals VRTX Q3 2025 earnings

Reported November 3, 2025 · After market close

Revenue$3.1BBeat by $16.9M
EPS$4.80Beat by $0.23
Revenue estimate$3.1B
EPS estimate$4.57

Next report

Nov 2, 2026 (in a month)
Revenue estimate$3.4B
EPS estimate$4.76

Financials

Q3 2025

Income statement

See full
Revenue$3.1B+11.0%
Gross profit$2.7B+11.9%
Operating income$1.2B+6.3%
Net income$1.1B+3.6%
EPS (diluted)$4.20+4.7%

Balance sheet

See full
Cash & equivalents$4.9B-5.7%
Total debt$1.8B+3.1%
Total equity$17.3B+10.8%
Total assets$24.9B+11.8%

Cash flow

See full
Operating cash flow$1.2B+1,108%
CapEx$101.8M+50.4%
Free cash flow$1.1B+677%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$100.41B-16.3%
Enterprise value$97.3B-16.5%
P/S8.6×-2.7×

Profitability

See full
Gross margin86.3%+0.2pp
FCF margin22.6%+14.9pp

Returns & leverage

See full
Debt / equity0.1×0.0×
Current ratio2.4×-0.1×

Segments

By product

See full
TRIKAFTA/KAFTRIO$2.7B+2.7%
ALYFTREK$247.0M—
Other CF product revenues$175.8M-5.9%

By segment

See full
Pharmaceuticals$3.1B+11.0%

FAQ

When did Vertex Pharmaceuticals report Q3 2025 earnings?
Vertex Pharmaceuticals (VRTX) reported Q3 2025 earnings on November 3, 2025 after market close.
What were Vertex Pharmaceuticals's Q3 2025 revenue and EPS?
Vertex Pharmaceuticals reported revenue of $3.1B and eps of $4.80 for Q3 2025.
Did Vertex Pharmaceuticals beat estimates in Q3 2025?
Revenue beat the consensus estimate of $3.1B by $16.9M. EPS beat the consensus estimate of $4.57 by $0.23.
How did Vertex Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.0% from $2.8B a year earlier and eps grew 9.6% from $4.38.
Where can I find Vertex Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0000875320-25-000230) and the 10-Q periodic report (0000875320-25-000232) directly on SEC EDGAR. The filing index links above go to sec.gov.